Leerink Partnrs Issues Optimistic Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Leerink Partnrs boosted their FY2025 earnings per share estimates for CRISPR Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($5.16) per share for the year, up from their previous estimate of ($5.53). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

A number of other equities research analysts have also issued reports on the company. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Thursday. Chardan Capital lowered their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday. The Goldman Sachs Group lowered their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday. Barclays increased their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Bank of America lowered their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus price target of $75.30.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $43.49 on Friday. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The firm has a market capitalization of $3.71 billion, a PE ratio of -15.37 and a beta of 1.67. The business has a 50-day moving average of $42.06 and a two-hundred day moving average of $46.25.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. ARK Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Capital International Investors increased its position in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after acquiring an additional 816,789 shares during the period. Baker BROS. Advisors LP increased its position in shares of CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares during the period. State Street Corp increased its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares during the period. Finally, Norges Bank acquired a new position in shares of CRISPR Therapeutics during the 4th quarter valued at $17,458,000. Institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.